Takeda Pharmaceutical (TAK) Interest Expenses (2017 - 2026)

Takeda Pharmaceutical's Interest Expenses history runs 10 years deep, the most recent figure standing at $944.5 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 234.42% year-over-year to $944.5 million in Q1 2026; TTM through Mar 2026 was $944.5 million, a 136.68% increase from a year earlier, with the FY2026 full-year figure at $984.0 million, down 28.65% from the prior year.
• Interest Expenses grew to $944.5 million in Q1 2026 per TAK's latest filing, from -$352.8 million in the prior quarter.
• Across five years, Interest Expenses topped out at $2.7 billion in Q1 2022 and bottomed at -$2.1 billion in Q3 2025.
• The 5-year median for Interest Expenses is -$428.9 million (2022), against an average of -$365.8 million.
• Across the five-year window, Interest Expenses slumped 206.97% in 2023 and soared 234.42% in 2026, its largest moves.
• Year by year, Interest Expenses stood at -$564.5 million in 2022, then surged by 41.04% to -$332.8 million in 2023, then grew by 0.6% to -$330.9 million in 2024, then slipped by 6.64% to -$352.8 million in 2025, then soared by 367.69% to $944.5 million in 2026.
• Per Business Quant, the three latest TAK Interest Expenses figures stand at $944.5 million (Q1 2026), -$352.8 million (Q4 2025), and -$2.1 billion (Q3 2025).